2. PROTAC Metabolic Enzyme/Protease NF-κB Immunology/Inflammation
  3. PROTACs HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)
  4. SH-26

SH-26 is a PHD1 PROTAC degrader with DC50s of 1.06 μM, 4.16 μM and 4.91 μM in MDA-MB-231, HepG2 and HEK-293T cells, respectively. SH-26 recruits CRBN to induce PHD1 degradation via the ubiquitin-proteasome system. SH-26 attenuates APAP (HY-66005)-triggered ROS accumulation, mitochondrial dysfunction, and NLRP3 inflammasome activation. SH-26 can be used for the research of acute liver injury.
(Pink: HIF/HIF Prolyl-Hydroxylase ligand (HY-183996); Blue: Cereblon ligand (HY-10984); Black: linker).

For research use only. We do not sell to patients.

SH-26

SH-26 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SH-26 Related Antibodies

Top Publications Citing Use of Products

View All PROTACs Isoform Specific Products:

View All Isoforms
von Hippel-Lindau (VHL) Cereblon MDM2 cIAP1

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Isoforms
HIF-1α HIF

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SH-26 is a PHD1 PROTAC degrader with DC50s of 1.06 μM, 4.16 μM and 4.91 μM in MDA-MB-231, HepG2 and HEK-293T cells, respectively. SH-26 recruits CRBN to induce PHD1 degradation via the ubiquitin-proteasome system. SH-26 attenuates APAP (HY-66005)-triggered ROS accumulation, mitochondrial dysfunction, and NLRP3 inflammasome activation. SH-26 can be used for the research of acute liver injury[1]. (Pink: HIF/HIF Prolyl-Hydroxylase ligand (HY-183996); Blue: Cereblon ligand (HY-10984); Black: linker).

IC50 & Target[1]

NLRP3 inflammasome

 

In Vitro

SH-26 (Compound 26) (0.25-10 μM; 2-72 h) induces concentration- and time-dependent PHD1 degradation in MDA-MB-231 cells, with a DC50 of 1.06 μM and a Dmax of 77.5% in 48 h[1].
SH-26 (0.25-50 μM; 48 h) induces concentration-dependent PHD1 degradation in HepG2 cells with a DC50 of 4.16 μM[1].
SH-26 (0-50 μM; 48 h) induces concentration-dependent PHD1 degradation in HEK-293T cells with a DC50 of 4.91 μM[1].
SH-26 (2-25 μM; 48 h) mediates PHD1 degradation in MDA-MB-231, HepG2, and HEK-293T cells in a ubiquitin-proteasome system-dependent manner that requires both PHD1 target engagement and CRBN recruitment[1].
SH-26 (1-25 μM; 4 h pretreatment) degrades PHD1 and PHD2 (but not PHD3) and stabilizes HIF-1α in APAP-challenged AML12 hepatocytes under normoxic conditions[1].
SH-26 (1-25 μM; 4 h pretreatment) exhibits enhanced concentration-dependent PHD1 degradation (DC50 = 0.13 μM) and stabilizes HIF-1α in APAP-challenged AML12 hepatocytes under hypoxic conditions[1].
SH-26 (1-50 μM; 4 h pretreatment) protects AML12 hepatocytes from APAP-induced injury in a concentration-dependent manner without inherent cytotoxicity[1].
SH-26 (1-25 μM; 4 h pretreatment) restores expression of HIF-1α target genes BNIP3 and SLC2A1, does not affect PHD1 mRNA levels, and suppresses IL-1β mRNA levels in APAP-challenged AML12 hepatocytes[1].
SH-26 (1-50 μM; 4 h pretreatment) dose-dependently degrades PHD1 and suppresses IL-1β protein levels in APAP-challenged AML12 hepatocytes[1].
SH-26 (1 μM; 24 h) degrades PHD1 and downregulates pro-inflammatory mediators IL-1β, IL-6, and TNF-α in LPS (HY-D1056)+IFN-γ-stimulated THP-1-derived M1 macrophages[1].
SH-26 (1-25 μM; 4 h pretreatment) dose-dependently reduces mitochondrial reactive oxygen species accumulation in APAP-challenged AML12 hepatocytes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SH-26 Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-231 breast cancer cells
Concentration: 0.25μM; 0.5 μM; 1 μM; 2 μM; 2.5 μM; 5 μM; 10 μM
Incubation Time: 2 h; 4 h; 8 h; 12 h; 24 h; 48 h; 72 h
Result: Induced 67% PHD1 degradation at 24 h, 70% at 48 h, and 80% at 72 h at 2 μM.
Induced concentration-dependent PHD1 degradation with a DC50 of 1.06 μM and a maximum degradation (Dmax) of 77.5%.
Caused significant degradation within 4 h, with maximal depletion achieved by 72 h.
Showed no hook effect at concentrations up to 10 μM.

Western Blot Analysis[1]

Cell Line: HepG2 hepatoma cells
Concentration: 0.25μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM; 10 μM
Incubation Time: 48 h
Result: Induced concentration-dependent PHD1 degradation with a DC50 of 4.16 μM.

Western Blot Analysis[1]

Cell Line: HEK-293T embryonic kidney cells
Concentration: 0.25μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM; 10 μM
Incubation Time: 48 h
Result: Induced concentration-dependent PHD1 degradation with a DC50 of 4.91 μM.

Western Blot Analysis[1]

Cell Line: MDA-MB-231, HepG2, and HEK-293T cells
Concentration: 2 μM; 25 μM
Incubation Time: 48 h
Result: Had its PHD1-degrading activity blocked in all three cell lines when cotreated with MG132, MLN4924, Takeda-54, or SH-28.

Western Blot Analysis[1]

Cell Line: AML12 hepatocytes
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM
Incubation Time: 4 h pretreatment
Result: Degraded PHD1 in a concentration-dependent manner.
Degraded PHD2 with a DC50 of 1.83 μM and a Dmax of 71.8%.
Did not degrade PHD3.
Stabilized HIF-1α in a concentration-dependent manner.

Western Blot Analysis[1]

Cell Line: AML12 hepatocytes
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM
Incubation Time: 4 h pretreatment
Result: Exhibited enhanced PHD1 degradation under hypoxia with a DC50 of 0.13 μM.
Stabilized HIF-1α in a concentration-dependent manner.

Cell Viability Assay[1]

Cell Line: AML12 hepatocytes (APAP-induced injury)
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM; 50 μM
Incubation Time: 4 h pretreatment
Result: Attenuated APAP-induced hepatotoxicity in a concentration-dependent manner.
Exhibited no inherent cytotoxicity at tested concentrations.

Real Time qPCR[1]

Cell Line: AML12 hepatocytes (APAP-induced injury)
Concentration: 1 μM; 5 μM; 25 μM
Incubation Time: 4 h pretreatment
Result: Restored BNIP3 mRNA to baseline levels and significantly upregulated SLC2A1 mRNA at 10 μM.
Did not alter PHD1 mRNA levels.
Dose-dependently suppressed IL-1β mRNA levels.

Western Blot Analysis[1]

Cell Line: AML12 hepatocytes (APAP-induced injury)
Concentration: 1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM; 50 μM
Incubation Time: 4 h pretreatment
Result: Dose-dependently degraded PHD1.
Dose-dependently suppressed IL-1β protein levels.
Parmacokinetics
Species Dose Route Cmax Tmax Plasma Concentration
Mice[1] 30 mg/kg i.p. 7 μM 0.5 h ~10 nM
In Vivo

SH-26 (Compound 26) (10-30 mg/kg; i.p.; single dose) confers robust hepatoprotective effects in APAP-induced acute liver injury[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (male, 8 weeks old, APAP-induced acute liver injury)[1]
Dosage: 10 mg/kg; 30 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CRE), and blood urea nitrogen (BUN) at 30 mg/kg.
Markedly attenuated APAP-induced hepatic damage, confirmed by histopathological analysis and necrotic area quantification at 10 mg/kg and 30 mg/kg.
Effectively reversed APAP-induced upregulation of PHD1 protein expression and induced robust PHD1 degradation in liver tissue at 10 mg/kg and 30 mg/kg.
Significantly reduced the upregulation of inflammasome components (NLRP3, GSDMD, cleaved caspase 1, cleaved IL-1β) at 10 mg/kg and 30 mg/kg.
Attenuated pro-apoptotic signals (increased BAX/BCL2 ratio, elevated cleaved caspase 3 levels) at 10 mg/kg and 30 mg/kg.
Significantly reduced liver tissue expression of immune cell markers LY6G, F4/80, CD31, and CD3 at 10 mg/kg and 30 mg/kg.
Molecular Weight

751.79

Formula

C38H41N9O8
SMILES

O=C1N(C(C2=CC=CC(NCCOCCOCCOCCNC(CCNC3=CC4=NC=NN4C(C5=C(C=C(C=C5)C#N)C)=C3)=O)=C21)=O)C6CCC(NC6=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SH-26 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SH-26SH26SH 26PROTACsHIF/HIF Prolyl-HydroxylaseReactive Oxygen Species (ROS)NOD-like Receptor (NLR)Hypoxia-inducible factorsHIFsHIF-PHubiquitin-proteasome systemNLRP3 inflammasomeMDA-MB-231 cellsAML12 hepatocytesTHP-1-derived M1 macrophagesHepG2 cellsPHD1cereblonHEK-293T cellsAPAP-induced acute liver injury modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SH-26
Cat. No.:
HY-183995
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.